Authored by Aurinia Pharma U.S., Inc.

Lupus nephritis (LN), a common and serious complication of systemic lupus erythematosus (SLE), occurs when there has been damage to the kidney.1 Kidney damage may result in proteinuria, the leakage of proteins into the urine.2 The level of proteinuria often indicates the degree of kidney injury and is used as a reliable indicator of treatment effectiveness.3 Promptly treating your patients with LN to guideline-recommended proteinuria targets is recommended for improving their long-term health outcomes.


Importance of Rapid Reduction

 The presence of protein in the urine has been shown to be independently associated with a greater risk of kidney failure and death.4

A long-term follow-up trial comparing mycophenolate mofetil and azathioprine as maintenance therapy showed that the reduction of proteinuria at 3, 6, and 12 months was highly predictive of a good long-term kidney prognosis.5 It was also shown that if 100 patients achieved a proteinuria level <0.5 mg/mg at 12 months, 92 of them would have preserved kidney function 10 years later.5


Treat to Target

Incorporating the current body of evidence, the most recent 2019 EULAR/ERA-EDTA guidelines for the management of LN recommend specific treatment targets to preserve kidney function.6 By 1 year after initiation of treatment for LN, physicians should target a urine protein-to-creatinine ratio (UPCR) below 0.5 mg/mg to 0.7 mg/mg.6

The guidelines also emphasize minimizing the cumulative steroid dose to reduce the risk of end-organ damage.6



Because time is of the essence with LN, guidelines recommend reducing proteinuria in your patients.

Visit to learn more about the actions you can take to improve outcomes for your patients with LN.

At Aurinia Pharma U.S., Inc., our mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune disease. Discover more about Aurinia at


ERA-EDTA=European Renal Association-European Dialysis and Transplant Association; EULAR=European League Against Rheumatism; LN=lupus nephritis; SLE=systemic lupus erythematosus; UPCR=urine protein-to-creatinine ratio.


References: 1. Almaani S, et al. Clin J Am Soc Nephrol. 2017;12(5):825-835. 2. KDIGO CKD Work Group. Kidney Int Suppl. 2013;3(1):1-150. 3. Palmer BF. Am J Nephrol. 2007;27(3):287-293. 4. Levey AS, et al. Kidney Int. 2011;80(1):17-28. 5. Tamirou F, et al. Ann Rheum Dis. 2016;75(3):526-531. 6. Fanouriakis A, et al. Ann Rheum Dis. 2020;79(6):713-723.


Copyright ©2021, Aurinia Pharma U.S., Inc.

All rights reserved. (10/21) US-NA-2100156

Posted by
  • As a speaker at the first ad hoc meeting of rheumatology practice managers gathered in a single small room at its infancy a decade ago, I’m amazed to see how NORM has blossomed into a high energy organization of depth and professional meetings with parallel break-out symposia between plenary sessions. NORM has truly come of age. This is where the “business” of rheumatology gets learned. The ”guildmanship” for rheumatology practice management is now strong.- Paul H. Caldron, DO, FACP, FACR, MBA, Arizona Arthritis and Rheumatology Associates
  • In a time of demanding changes in the management of medical practices in the US, NORM has been a lifesaver to the community of Rheumatology practices.  NORM has allowed our practice to stay ahead of the many demands of CMS and others payors and has ensured that our practice remains cognizant of new issues that arise in HIPPA compliance, human resources and medical billing to name a few. Sending our Practice Manager to NORM's conferences has been cost-effective and beneficial to our practice because she returns to our office with an abundance of information that otherwise would have taken months to compile. Every Rheumatology practice that wishes to stay on top of emerging issues in practice management should consider sending a member of their staff to NORM's conference.- Michael S. Rosen M.D., Chester County Rheumatology PC
  • Thanks to all those wonderful people in the NORM Network who respond to emails, offering their advice, experience, time, and support ... I haven't even been a member a full year yet and I am amazed at the dedication of everyone who responds to helping via emails and the NORM Organization itself! I have barely had a chance to explore the resources and I have yet to really dive into requests for help still I am silently learning so much and do occasionally offer what I can! Thank you all!- Cheryl Piambino, Kenneth E. Bresky, DO

What We Offer

We’re adding value to practices across the nation by creating a thriving community of rheumatology managers and physicians.

Membership Benefits

Become a Member

Annual Conference

Conference Registration